April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
A PPAR Endogenous Ligand 15-deoxy-12,14-Prostaglandin J2 Inhibits TGF-β-mediated Responses In Human Orbital Fibroblasts
Author Affiliations & Notes
  • Naxin Guo
    Ophthalmology, URMC, Flaum Eye Institute, Rochester, New York
  • Steven E. Feldon
    Ophthalmology-Med Ctr, University of Rochester, Rochester, New York
  • Richard P. Phipps
    Ophthalmology, URMC, Flaum Eye Institute, Rochester, New York
  • Footnotes
    Commercial Relationships  Naxin Guo, None; Steven E. Feldon, None; Richard P. Phipps, None
  • Footnotes
    Support  NIH Grant EY017123, EY011708, Rochester Tissue/Eye bank and Research to Prevent Blindness Foundation Grant
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5103. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Naxin Guo, Steven E. Feldon, Richard P. Phipps; A PPAR Endogenous Ligand 15-deoxy-12,14-Prostaglandin J2 Inhibits TGF-β-mediated Responses In Human Orbital Fibroblasts. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5103.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Infiltration of white blood cells and accumulation of extracellular matrix, especially hyaluronan (HA) in orbital tissue are characteristic of Thyroid eye disease (TED). Transforming growth factor beta (TGF-β) is up-regulated in orbital tissue from patients with TED where it acts as a key inducer of fibrosis by enhancing extracellular matrix production. 15-deoxy-Δ12,14-Prostaglandin J2 (15d-PGJ2) is an endogenous Peroxisome Proliferator-Activated Receptor gamma (PPARγ) ligand that exhibits diverse biological effects, including anti-inflammatory and anti-fibrogenic activities. In this study, we report that 15d-PGJ2 inhibits TGF-β-mediated responses in orbital fibroblasts.

Methods: : Primary orbital fibroblasts were isolated from Graves’ disease patients undergoing orbital decompression surgery. The cells were grown in RPMI 1640 media containing 10% FBS. The amount of HA in the cell culture supernatant and pericellular extraction was measured by ELISA. Activated human T cell expression of CD44 was measured by flow cytometry. T cell adhesion to orbital fibroblasts was detected by measuring fluorescent intensity of bound calcein-AM labeled T cells. A fibrotic marker, alpha smooth muscle actin (α-SMA), was detected using western blot.

Results: : TGF-β strongly induced HA levels in conditioned medium and pericellular extracts of human orbital fibroblasts after 24 hour treatment compared to untreated control. TGF-β also enhanced fibroblast-T cell adhesion and this cell-cell adhesion was inhibited by orbital fibroblast pre-incubation with hyaluronidase or HA synthase 2 siRNA, indicating that newly synthesized HA mediated the adhesion, probably through the interaction with its cellular receptor CD44 on the T cell surface. As a key inducer of fibrosis, TGF-β significantly up-regulated α-SMA protein levels in orbital fibroblasts. Remarkably, addition of the PPARγ ligand 15d-PGJ2 to TGF-β treated orbital fibroblasts blocked HA synthesis and T cell-fibroblast adhesion in a dose-dependent manner. In addition, 15d-PGJ2 also inhibited TGF-β induced α-SMA expression.

Conclusions: : Our data reveal that 15d-PGJ2 is a potent inhibitor of TGF-β mediated pro-inflammatory and fibrogenic activities in orbital fibroblasts. Newly synthesized HA plays an impotent role in T cell-fibroblast adhesion. The ability to block HA synthesis with inhibitors such as 15d-PGJ2, therefore, presents a potential for therapeutic application.

Keywords: extracellular matrix • cell adhesions/cell junctions • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×